Histone Acetylation as a Regenerative Target in the Dentine-Pulp Complex

Yamauchi, Y.; Cooper, Paul R.; Shimizu, Emi; Kobayashi, Yoshifumi; Smith, Anthony J.; Duncan, Henry F.

doi:10.3389/fgene.2020.00001

Cited by 84 publications

(60 citation statements)

References 106 publications

(144 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inspection of the ERG2 , ERG3 , ERG5 , and ERG6 coding sequence in C. auris genomes from Italy revealed no mutations previously associated with amphotericin B resistance [ 28 , 29 , 30 ]. Conversely, the presence of the same amino acid substitution ERG11 (K143R), being previously shown to reduce azole susceptibility [ 3 ], has been detected in all isolates. A genetic alteration recently associated with a high-level resistance to fluconazole, due to a transcriptional upregulation of ABC-type efflux pumps, was additionally identified in all sequenced isolates in TAC1B (A640V) [ 31 ].…”

Section: Resultsmentioning

confidence: 88%

“…Over past years, Candida auris has emerged as a fungal pathogen of major concern, frequently showing a multidrug-resistant (MDR) phenotype and being recognized as an important cause of nosocomial outbreaks of invasive infections worldwide [ 2 ]. The global dissemination of this pathogen has been initially attributed to the simultaneous emergence of four major phylogenetically distinct lineages, showing a specific geographical distribution and including: South Asian (I), East Asian (II), African (III), and South American (IV) clades [ 3 ]. A potential fifth clade of Iranian origin has been also described [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Molecular Epidemiological Investigation of a Nosocomial Cluster of C. auris: Evidence of Recent Emergence in Italy and Ease of Transmission during the COVID-19 Pandemic

Pilato

Codda

Ball

et al. 2021

JoF

View full text Add to dashboard Cite

Candida auris is an emerging MDR pathogen raising major concerns worldwide. In Italy, it was first and only identified in July 2019 in our hospital (San Martino Hospital, Genoa), where infection or colonization cases have been increasingly recognized during the following months. To gain insights into the introduction, transmission dynamics, and resistance traits of this fungal pathogen, consecutive C. auris isolates collected from July 2019 to May 2020 (n = 10) were subjected to whole-genome sequencing (WGS) and antifungal susceptibility testing (AST); patients’ clinical and trace data were also collected. WGS resolved all isolates within the genetic clade I (South Asian) and showed that all but one were part of a cluster likely stemming from the index case. Phylogenetic molecular clock analyses predicted a recent introduction (May 2019) in the hospital setting and suggested that most transmissions were associated with a ward converted to a COVID-19-dedicated ICU during the pandemic. All isolates were resistant to amphotericin B, voriconazole, and fluconazole at high-level, owing to mutations in ERG11(K143R) and TACB1(A640V). Present data demonstrated that the introduction of MDR C. auris in Italy was a recent event and suggested that its spread could have been facilitated by the COVID-19 pandemic. Continued efforts to implement stringent infection prevention and control strategies are warranted to limit the spread of this emerging pathogen within the healthcare system.

show abstract

Section: Resultsmentioning

confidence: 88%

Section: Introductionmentioning

confidence: 99%

Molecular Epidemiological Investigation of a Nosocomial Cluster of C. auris: Evidence of Recent Emergence in Italy and Ease of Transmission during the COVID-19 Pandemic

Pilato

Codda

Ball

et al. 2021

JoF

View full text Add to dashboard Cite

show abstract

“…So far, no ACE2 genetic variant has been associated to increased risk of SARS-CoV-2 infection or to the severe clinical presentation of COVID-19 [ 16 , 17 ]. An Italian study comparing 131 COVID-19 and 258 controls without the disease found that higher ACE2 variability was present in the control group [ 18 ] suggesting that variants in ACE2 could explain some differences in the susceptibility among different individuals.…”

Section: Ace2 Genementioning

confidence: 99%

ACE2: the molecular doorway to SARS-CoV-2

López-Léon²,

et al. 2020

View full text Add to dashboard Cite

The angiotensin-converting enzyme 2 (ACE2) is the host functional receptor for the new virus SARS-CoV-2 causing Coronavirus Disease 2019. ACE2 is expressed in 72 different cell types. Some factors that can affect the expression of the ACE2 are: sex, environment, comorbidities, medications (e.g. anti-hypertensives) and its interaction with other genes of the renin-angiotensin system and other pathways. Different factors can affect the risk of infection of SARS-CoV-2 and determine the severity of the symptoms. The ACE2 enzyme is a negative regulator of RAS expressed in various organ systems. It is with immunity, inflammation, increased coagulopathy, and cardiovascular disease. In this review, we describe the genetic and molecular functions of the ACE2 receptor and its relation with the physiological and pathological conditions to better understand how this receptor is involved in the pathogenesis of COVID-19. In addition, it reviews the different comorbidities that interact with SARS-CoV-2 in which also ACE2 plays an important role. It also describes the different factors that interact with the virus that have an influence in the expression and functional activities of the receptor. The goal is to provide the reader with an understanding of the complexity and importance of this receptor.

show abstract

“…Genetic markers have been explored as a predictor of the antitumor response or chemoresistance, and the use of next-generation sequencing provided a new perspective for marker identification. Several markers were previously associated with BC drug sensitivity or resistance [ 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 ]. Gong et al [ 62 ] evaluated a cohort of 421 patients with luminal A BC from two different stages using genotyping from peripheral blood.…”

Section: Markers Associated With the Chemotherapy Responsementioning

confidence: 99%

Mechanisms of Resistance to Chemotherapy in Breast Cancer and Possible Targets in Drug Delivery Systems

et al. 2020

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most important cancers worldwide, and usually, chemotherapy can be used in an integrative approach. Usually, chemotherapy treatment is performed in association with surgery, radiation or hormone therapy, providing an increased outcome to patients. However, tumors can develop resistance to different drugs, progressing for a more aggressive phenotype. In this scenario, the use of nanocarriers could help to defeat tumor cell resistance, providing a new therapeutic perspective for patients. Thus, this systematic review aims to bring the molecular mechanisms involved in BC chemoresistance and extract from the previous literature information regarding the use of nanoparticles as potential treatment for chemoresistant breast cancer.

show abstract

Histone Acetylation as a Regenerative Target in the Dentine-Pulp Complex

Cited by 84 publications

References 106 publications

Molecular Epidemiological Investigation of a Nosocomial Cluster of C. auris: Evidence of Recent Emergence in Italy and Ease of Transmission during the COVID-19 Pandemic

Molecular Epidemiological Investigation of a Nosocomial Cluster of C. auris: Evidence of Recent Emergence in Italy and Ease of Transmission during the COVID-19 Pandemic

ACE2: the molecular doorway to SARS-CoV-2

Mechanisms of Resistance to Chemotherapy in Breast Cancer and Possible Targets in Drug Delivery Systems

Contact Info

Product

Resources

About